{"id":65293,"date":"2026-05-14T14:05:10","date_gmt":"2026-05-14T06:05:10","guid":{"rendered":"https:\/\/flcube.com\/?p=65293"},"modified":"2026-05-14T14:05:11","modified_gmt":"2026-05-14T06:05:11","slug":"innocare-pharma-doses-first-patient-in-icp-054-zb021-trial-novel-oral-il-17aa-af-inhibitor-shows-promise-for-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=65293","title":{"rendered":"InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial \u2013 Novel Oral IL-17AA\/AF Inhibitor Shows Promise for Autoimmune Diseases"},"content":{"rendered":"\n<p><strong>InnoCare Pharma<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9969:HKG\">HKG: 9969<\/a>) announced the dosing of the first subject in a clinical study for its <strong>ICP-054 (ZB021)<\/strong> in China. The compound is a <strong>novel, oral, highly potent, and selective IL-17AA\/AF inhibitor<\/strong> with significant therapeutic potential in <strong>autoimmune and inflammatory diseases<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-milestone\">Clinical Development Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>InnoCare Pharma (HKG: 9969)<\/td><\/tr><tr><td><strong>Trial Status<\/strong><\/td><td>First patient dosed<\/td><\/tr><tr><td><strong>Geography<\/strong><\/td><td>China<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>ICP-054 (ZB021)<\/td><\/tr><tr><td><strong>Therapeutic Area<\/strong><\/td><td>Autoimmune and inflammatory diseases<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Early clinical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Oral, highly potent, selective IL-17AA\/AF inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Dual Targeting:<\/strong> Effectively blocks signaling of both <strong>IL-17AA homodimers<\/strong> and <strong>IL-17AF heterodimers<\/strong><\/li>\n\n\n\n<li><strong>Anti-inflammatory Effects:<\/strong> Inhibits release of pro-inflammatory cytokines and chemokines<\/li>\n\n\n\n<li><strong>Skin-Specific Benefits:<\/strong> Reduces excessive proliferation of skin keratinocytes and inflammatory cell infiltration<\/li>\n\n\n\n<li><strong>Clinical Impact:<\/strong> Improves skin lesions and suppresses development of autoimmune and inflammatory diseases<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Oral formulation offering patient convenience advantages over injectable biologics<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-amp-global-commercialization\">Strategic Partnership &amp; Global Commercialization<\/h2>\n\n\n\n<p><strong>Licensing Agreement with Zenas BioPharma (October 2025):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Partner:<\/strong> Zenas BioPharma, Inc. (US-based)<\/li>\n\n\n\n<li><strong>Territory:<\/strong> Exclusive rights for regions <strong>outside Greater China and Southeast Asia<\/strong><\/li>\n\n\n\n<li><strong>Scope:<\/strong> Development, manufacturing, and commercialization rights<\/li>\n\n\n\n<li><strong>Strategic Rationale:<\/strong> Leverages Zenas&#8217;s global development expertise while retaining key Asian markets<\/li>\n<\/ul>\n\n\n\n<p>This partnership structure allows InnoCare to maintain control over high-value Asian markets while benefiting from Zenas&#8217;s international capabilities for global expansion.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<p><strong>IL-17 Inhibitor Market Dynamics:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Established class with proven efficacy in psoriasis, psoriatic arthritis, and other autoimmune conditions<\/li>\n\n\n\n<li>Current market dominated by injectable biologics (secukinumab, ixekizumab, brodalumab)<\/li>\n\n\n\n<li><strong>Oral administration<\/strong> represents significant differentiation and potential competitive advantage<\/li>\n\n\n\n<li>Dual inhibition of both IL-17AA and IL-17AF may provide broader efficacy compared to selective inhibitors<\/li>\n<\/ul>\n\n\n\n<p><strong>Commercial Opportunity:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Large and growing autoimmune disease market with substantial unmet needs<\/li>\n\n\n\n<li>Oral formulations typically command premium pricing and higher patient adherence<\/li>\n\n\n\n<li>First-mover advantage in oral IL-17 inhibition could establish significant market position<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-strategy-amp-pipeline-implications\">Development Strategy &amp; Pipeline Implications<\/h2>\n\n\n\n<p>The initiation of clinical testing represents a critical milestone in InnoCare&#8217;s diversification beyond its oncology-focused pipeline into autoimmune and inflammatory diseases. Success with ICP-054 could establish the company as a multi-therapeutic area player with both oncology and immunology franchises.<\/p>\n\n\n\n<p>The dual-homodimer\/heterodimer inhibition approach may provide superior efficacy compared to existing selective IL-17A inhibitors, potentially addressing patients who respond inadequately to current therapies.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and therapeutic potential of ICP-054. Actual results may differ due to risks including clinical trial outcomes, regulatory requirements, competitive dynamics, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688428_20260514_2D90.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688428_20260514_2D90.\"><\/object><a id=\"wp-block-file--media-39674dfe-f767-427d-a4dc-b2f345620178\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688428_20260514_2D90.pdf\">688428_20260514_2D90<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/05\/688428_20260514_2D90.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-39674dfe-f767-427d-a4dc-b2f345620178\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>InnoCare Pharma (HKG: 9969) announced the dosing of the first subject in a clinical study&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,919,327],"class_list":["post-65293","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-9969","tag-innocare-pharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial \u2013 Novel Oral IL-17AA\/AF Inhibitor Shows Promise for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"InnoCare Pharma (HKG: 9969) announced the dosing of the first subject in a clinical study for its ICP-054 (ZB021) in China. The compound is a novel, oral, highly potent, and selective IL-17AA\/AF inhibitor with significant therapeutic potential in autoimmune and inflammatory diseases.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=65293\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial \u2013 Novel Oral IL-17AA\/AF Inhibitor Shows Promise for Autoimmune Diseases\" \/>\n<meta property=\"og:description\" content=\"InnoCare Pharma (HKG: 9969) announced the dosing of the first subject in a clinical study for its ICP-054 (ZB021) in China. The compound is a novel, oral, highly potent, and selective IL-17AA\/AF inhibitor with significant therapeutic potential in autoimmune and inflammatory diseases.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=65293\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-14T06:05:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-14T06:05:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65293#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65293\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial \u2013 Novel Oral IL-17AA\\\/AF Inhibitor Shows Promise for Autoimmune Diseases\",\"datePublished\":\"2026-05-14T06:05:10+00:00\",\"dateModified\":\"2026-05-14T06:05:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65293\"},\"wordCount\":438,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 9969\",\"InnoCare Pharma\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65293#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65293\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=65293\",\"name\":\"InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial \u2013 Novel Oral IL-17AA\\\/AF Inhibitor Shows Promise for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-14T06:05:10+00:00\",\"dateModified\":\"2026-05-14T06:05:11+00:00\",\"description\":\"InnoCare Pharma (HKG: 9969) announced the dosing of the first subject in a clinical study for its ICP-054 (ZB021) in China. The compound is a novel, oral, highly potent, and selective IL-17AA\\\/AF inhibitor with significant therapeutic potential in autoimmune and inflammatory diseases.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65293#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=65293\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=65293#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial \u2013 Novel Oral IL-17AA\\\/AF Inhibitor Shows Promise for Autoimmune Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial \u2013 Novel Oral IL-17AA\/AF Inhibitor Shows Promise for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","description":"InnoCare Pharma (HKG: 9969) announced the dosing of the first subject in a clinical study for its ICP-054 (ZB021) in China. The compound is a novel, oral, highly potent, and selective IL-17AA\/AF inhibitor with significant therapeutic potential in autoimmune and inflammatory diseases.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=65293","og_locale":"en_US","og_type":"article","og_title":"InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial \u2013 Novel Oral IL-17AA\/AF Inhibitor Shows Promise for Autoimmune Diseases","og_description":"InnoCare Pharma (HKG: 9969) announced the dosing of the first subject in a clinical study for its ICP-054 (ZB021) in China. The compound is a novel, oral, highly potent, and selective IL-17AA\/AF inhibitor with significant therapeutic potential in autoimmune and inflammatory diseases.","og_url":"https:\/\/flcube.com\/?p=65293","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-14T06:05:10+00:00","article_modified_time":"2026-05-14T06:05:11+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=65293#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=65293"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial \u2013 Novel Oral IL-17AA\/AF Inhibitor Shows Promise for Autoimmune Diseases","datePublished":"2026-05-14T06:05:10+00:00","dateModified":"2026-05-14T06:05:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=65293"},"wordCount":438,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 9969","InnoCare Pharma"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=65293#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=65293","url":"https:\/\/flcube.com\/?p=65293","name":"InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial \u2013 Novel Oral IL-17AA\/AF Inhibitor Shows Promise for Autoimmune Diseases - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-14T06:05:10+00:00","dateModified":"2026-05-14T06:05:11+00:00","description":"InnoCare Pharma (HKG: 9969) announced the dosing of the first subject in a clinical study for its ICP-054 (ZB021) in China. The compound is a novel, oral, highly potent, and selective IL-17AA\/AF inhibitor with significant therapeutic potential in autoimmune and inflammatory diseases.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=65293#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=65293"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=65293#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Pharma Doses First Patient in ICP-054 (ZB021) Trial \u2013 Novel Oral IL-17AA\/AF Inhibitor Shows Promise for Autoimmune Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=65293"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65293\/revisions"}],"predecessor-version":[{"id":65295,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/65293\/revisions\/65295"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=65293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=65293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=65293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}